Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.4% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment reporting

Analytics

Phase 1
3(50.0%)
Phase 2
2(33.3%)
Phase 1/2
1(16.7%)
6Total
Phase 1(3)
Phase 2(2)
Phase 1/2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT00328614Phase 1Completed

Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer

Role: collaborator

NCT00710970Phase 2Completed

Tamoxifen for Progressive Transitional Cell Carcinoma Following Previous Chemotherapy Treatment

Role: collaborator

NCT00429507Phase 2Completed

Sm-EDTMP and Autologous Peripheral Blood Stem Cell Transplantation for Breast Cancer Patients With Bone Only Metastases

Role: collaborator

NCT00559429Phase 1Completed

Study of Docetaxel +153 Sm-EDTMP in Patients With Hormone-Refractory Prostate Cancer

Role: collaborator

NCT00121095Phase 1/2Unknown

Study of Samarium Sm-153 Lexidronam Combined With Docetaxel for Patients With Prostate Cancer

Role: lead

NCT00441571Phase 1Unknown

Safety Study of a Radiolabeled Antibody (7E11) in Patients With Progressive Hormone Refractory Prostate Cancer

Role: lead

All 6 trials loaded